Os therapies announces positive data for ost-her2 in the treatment of unresected osteosarcoma in dogs opening the potential for use as front-line therapy in humans

Yet to be published data from clinical study combining ost-her2 with palliative radiation in dogs with unresected, primary osteosarcoma shows clinical and radiographic arrest of the primary tumor, delayed pulmonary metastases and prolonged overall survival of greater than 500 days in 5 out of 15 dogs. data from new publication in the journal "molecular therapy" show ost-her2 induces strong innate and cytotoxic immune responses beginning at the 1 st dose of 3 dose regimen, that correlate with prevention of metastasis and long-term survival in dogs with resected primary osteosarcoma.
OST Ratings Summary
OST Quant Ranking